"Granules India - FDA अप्रूवल्स का Pharma Champion, स्थिर वृद्धि का वादा!"

Detailed Technical Analysis:

Granules maintains a Strong Buy daily rating with 9 buy signals dominating across moving averages versus zero sells, though oscillators introduce caution: CCI(14) -109 Sell, Highs/Lows(14) -3 Sell, Ultimate Oscillator 46 Sell, ROC -1.3 Sell, Bull/Bear Power -8 Sell amid high ATR(14) 4.6 volatility. Price action consolidates near upper annual band above all key SMAs (20D ₹584 Neutral, 50D ₹568 Neutral, 100D ₹542 Neutral, 200D ₹515 Neutral), with trend shifting from strong bullish to mildly bullish on MACD remaining positive weekly/monthly (line above signal), signaling sustained underlying momentum despite short-term moderation. Pivot levels guide near-term action: Classic S3 ₹592, S2 ₹602, S1 ₹607, Pivot ₹616, R1 ₹621, R2 ₹630, R3 ₹636 - current positioning tests R1 hold for breakout validity toward 52-week high retest. Weekly volume supports resilience near highs, with MarketsMOJO score upgraded to Buy 70/100 incorporating technicals, but overbought risks from recent 8% monthly surge demand pullback vigilance before further upside. Today's Price Movement Analysis: No major explosive move today - shares edged +1.15% to ₹612 amid range-bound action ₹607-623, continuing consolidation pattern post-Jan 5 minor -0.56% dip to ₹616 from prior ₹619, driven by lingering positivity from USFDA Establishment Inspection Report (EIR) clearance at Jeedimetla, Q2 profit surge 34%, and ADHD treatment approvals for US arm rather than acute news catalyst. Technical momentum shift to mildly bullish with outperformance (monthly +8% vs Sensex +0.7%) supports steady grind higher near highs without volatility spike.